download chevron-down chevron-right chevron-with-circle-down chevron-with-circle-up check circle-with-minus circle-with-plus export help-with-circle inbox link mail old-phone star-outlined star user v-card close close close Back to top
Top

Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy

CMS Measure ID
CMS645v1
Version
1
NQF Number
None
Measure Description

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Initial Population

Male patients with a diagnosis of prostate cancer and an order for or who are actively undergoing ADT for a period greater than or equal to 12 months with an office visit during the measurement period

Denominator Statement
Denominator Exclusions

None

Numerator Statement

Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment

Numerator Exclusions

None

Denominator Exceptions

Patient refused recommendation for a bone density evaluation after the start of ADT therapy

Measure Steward
Next Version
Measure Scoring
Measure Type
Improvement Notation

A higher score indicates better quality

Guidance

In order to capture the practitioner's intent of androgen deprivation therapy (ADT) for a period of 12 months or greater, the custom HCPCS code of J1950,cont was added to the $ADT variable as Procedure, Order. Each EHR can define this custom code as intended therapy for 12 months or greater with the practitioner indicating this code at the start of the intended therapy.

Notes

Not available for Medicaid EHR Incentive Program for Eligible Professionals

Specifications

Last Updated: Jul 22, 2019